VRDN
Income statement / Annual
Last year (2025), Viridian Therapeutics Inc's total revenue was $70.85 M,
an increase of 23,359.93% from the previous year.
In 2025, Viridian Therapeutics Inc's net income was -$342.60 M.
See Viridian Therapeutics Inc,s key income statements, including revenue, expenses, profit, and income.
| Period |
FY-2025
|
FY-2024
|
FY-2023
|
FY-2022
|
FY-2021
|
FY-2020
|
FY-2019
|
FY-2018
|
FY-2017
|
FY-2016
|
| Period Ended |
12/31/2025 |
12/31/2024 |
12/31/2023 |
12/31/2022 |
12/31/2021 |
12/31/2020 |
12/31/2019 |
12/31/2018 |
12/31/2017 |
12/31/2016 |
| Operating Revenue |
$70.85 M |
$302.00 K |
$314.00 K |
$1.77 M |
$2.96 M |
$1.05 M |
$4.46 M |
$8.39 M |
$4.00 M |
$3.34 M |
| Cost of Revenue |
$1.16 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$28.30 M
|
$0.00
|
$30.42 M
|
$19.62 M
|
$2.55 M
|
| Gross Profit |
$69.69 M
|
$302.00 K
|
$314.00 K
|
$1.77 M
|
$2.96 M
|
-$27.25 M
|
$4.46 M
|
-$22.04 M
|
-$15.62 M
|
$789.00 K
|
| Gross Profit Ratio |
0.98
|
1
|
1
|
1
|
1
|
-25.96
|
1
|
-2.63
|
-3.9
|
0.24
|
| Research and Development Expenses |
$338.93 M
|
$238.25 M
|
$159.77 M
|
$100.89 M
|
$56.89 M
|
$28.30 M
|
$34.79 M
|
$30.42 M
|
$19.62 M
|
$888.00 K
|
| General & Administrative Expenses |
$0.00
|
$61.08 M
|
$95.00 M
|
$35.18 M
|
$25.81 M
|
$13.27 M
|
$11.65 M
|
$11.05 M
|
$10.91 M
|
$7.91 M
|
| Selling & Marketing Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$1.67 M
|
| Selling, General & Administrative Expenses |
$95.32 M
|
$61.08 M
|
$95.00 M
|
$35.18 M
|
$25.81 M
|
$13.27 M
|
$11.65 M
|
$11.05 M
|
$10.91 M
|
$9.58 M
|
| Other Expenses |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$41.56 M
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
| Operating Expenses |
$433.08 M
|
$299.34 M
|
$254.76 M
|
$136.08 M
|
$82.69 M
|
$83.13 M
|
$46.44 M
|
$41.47 M
|
$30.54 M
|
$10.46 M
|
| Cost And Expenses |
$434.24 M
|
$299.34 M
|
$254.76 M
|
$136.08 M
|
$82.69 M
|
$111.43 M
|
$46.44 M
|
$41.47 M
|
$30.54 M
|
$13.01 M
|
| Interest Income |
$27.40 M
|
$32.13 M
|
$18.56 M
|
$4.92 M
|
$318.00 K
|
$173.00 K
|
$941.00 K
|
$1.25 M
|
$403.00 K
|
$0.00
|
| Interest Expense |
$4.95 M
|
$3.05 M
|
$1.85 M
|
$486.00 K
|
$3.00 K
|
$508.00 K
|
$835.00 K
|
$873.00 K
|
$383.00 K
|
$95.00 K
|
| Depreciation & Amortization |
$1.16 M
|
$1.24 M
|
$522.00 K
|
$255.00 K
|
$120.00 K
|
$239.00 K
|
$288.00 K
|
$281.00 K
|
$308.00 K
|
$341.00 K
|
| EBITDA |
-$336.49 M |
-$265.66 M |
-$235.37 M |
-$129.13 M |
-$79.29 M |
-$40.28 M |
-$40.75 M |
-$31.55 M |
-$25.82 M |
-$12.51 M |
| EBITDA Ratio |
-4.75
|
-879.68
|
-749.57
|
-72.87
|
-26.76
|
-38.36
|
-9.13
|
-3.76
|
-6.45
|
-3.75
|
| Operating Income Ratio |
-5.13
|
-990.18
|
-810.35
|
-75.79
|
-26.91
|
-105.12
|
-9.41
|
-3.95
|
-6.63
|
-3.75
|
| Total Other Income/Expenses Net |
$20.79 M
|
$29.09 M
|
$16.72 M
|
$4.43 M
|
$315.00 K
|
-$335.00 K
|
$106.00 K
|
$381.00 K
|
$20.00 K
|
-$166.00 K
|
| Income Before Tax |
-$342.60 M
|
-$269.95 M
|
-$237.73 M
|
-$129.87 M
|
-$79.41 M
|
-$110.72 M
|
-$41.87 M
|
-$32.70 M
|
-$26.51 M
|
-$12.67 M
|
| Income Before Tax Ratio |
-4.84
|
-893.87
|
-757.11
|
-73.29
|
-26.8
|
-105.44
|
-9.39
|
-3.9
|
-6.62
|
-3.8
|
| Income Tax Expense |
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$0.00
|
$95.00 K
|
$95.00 K
|
| Net Income |
-$342.60 M
|
-$269.95 M
|
-$237.73 M
|
-$129.87 M
|
-$79.41 M
|
-$110.72 M
|
-$41.87 M
|
-$32.70 M
|
-$26.51 M
|
-$12.67 M
|
| Net Income Ratio |
-4.84
|
-893.87
|
-757.11
|
-73.29
|
-26.8
|
-105.44
|
-9.39
|
-3.9
|
-6.62
|
-3.8
|
| EPS |
-3.32 |
-3.98 |
-5.31 |
-3.91 |
-6.66 |
-31.2 |
-20.31 |
-16.57 |
-20.66 |
-17.57 |
| EPS Diluted |
-3.32 |
-3.98 |
-5.31 |
-3.91 |
-6.66 |
-31.2 |
-20.31 |
-16.57 |
-20.66 |
-17.57 |
| Weighted Average Shares Out |
$84.80 M
|
$67.89 M
|
$44.76 M
|
$32.09 M
|
$11.92 M
|
$3.56 M
|
$2.09 M
|
$1.97 M
|
$1.28 M
|
$721.41 K
|
| Weighted Average Shares Out Diluted |
$84.80 M
|
$67.89 M
|
$44.76 M
|
$32.09 M
|
$11.92 M
|
$3.56 M
|
$2.09 M
|
$1.97 M
|
$1.28 M
|
$721.41 K
|
| Link |
|
|
|
|
|
|
|
|
|
|
